SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong5/26/2016 8:53:48 AM
  Read Replies (1) of 3661
 
Ionis Pharmaceuticals (NASDAQ: IONS) reports that strategic alliance partner GlaxoSmithKline (NYSE: GSK) has elected not to proceed with a Phase 3 clinical trial, CARDIO-TTR, assessing antisense drug IONIS-TTRrx in patients with transthyretin (TTR) amyloid cardiomyopathy. The trial was placed on clinical hold by the FDA last month due to safety issues identified in Ionis' Phase 3 study, NEURO-TTR, evaluating IONIS-TTRrx in TTR familial amyloid polyneuropathy (FAP). Glaxo says it will evaluate its options once more data are available from ongoing studies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News